Clinical Situations at High Risk of Placenta Accreta / Percreta
NCT ID: NCT02010229
Last Updated: 2025-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
674 participants
OBSERVATIONAL
2013-11-04
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This population-based study conducted in 8 French regions will also provide valid estimation of the incidence of placenta accreta among all parturients and among "at risk "women. Finally, a psychological evaluation of these women up to 1 year after delivery will provide information on the impact of these conditions on women, beyond somatic complications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Factors, Prognosis and Prediction Models for Placenta Accreta Without Prior Cesarean Section
NCT06383923
Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum
NCT07283042
Evaluation of Planned Conservative Surgical Management of Placenta Accreta Spectrum in Women's Health Center, Assiut University Hospital
NCT06712576
Total Placenta Previa Associated With the Placenta Accreta Spectrum.
NCT06219564
Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population
NCT02302573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives: The primary objectives are to identify individual risk factors for maternal morbidity, as well as risk factors related to types of management and healthcare facilities for postpartum hemorrhage (PPH). Secondary objectives are to 1) determine the prevalence of placenta accreta among women at risk; 2) assess the predictive value of ultrasound and MRI for the diagnosis of placenta accreta in this population; 3) evaluate psychological impact and physical complications; 4) report maternal physical complications during the year after delivery.
Design: Population-based prospective observational study of pregnant women with a placenta inserted at a uterine scar Setting; A total of 166 centers in 8 French regions, with 260,000 deliveries annually.
Methods: We expect to include 570 women at risk of placenta accreta in two years, of whom approximately 100 (20%) will have placenta accreta.
Main outcome measures: The primary outcome measure is severe maternal hemorrhage; secondary outcome measures are maternal morbidity and deaths, predictive value of ultrasound and MRI, and psychological evaluations at 1, 6 and 12 months after delivery.
Conclusion: This study will be the first prospective population-based study to include women at risk of placenta accreta and to investigate incidence, prenatal detection, type of management, morbidity and maternal psychological consequences.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
women at high risk of placenta accreta
Parturient women with placenta praevia and at least one previous caesarean delivery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* delivering in a maternity unit of the 11 participating perinatal networks.
* With a placenta praevia and at least one previous cesarean delivery, and / or having a placenta accreta
* aged 18 or more
Exclusion Criteria
* not understanding French.
* refusing to participate in the study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inserm U953 (Epidemiological research unit on perinatal health and women's and children's health) Paris, France
UNKNOWN
University Hospital, Angers
OTHER_GOV
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles Kayem, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Louis Mourier University Hospital (APHP), department of gynaecology and obstetrics, Colombes, France
Loic Sentilhes, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Angers University Hospital, department of gynaecology and obstetrics, France
Catherine Deneux-Tharaux, MD, PhD
Role: STUDY_DIRECTOR
INSERM U953, Epidemiological research unit on perinatal health and children's and women's health, Paris, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Louis Mourier (APHP)
Colombes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sentilhes L, Seco A, Azria E, Beucher G, Bonnet MP, Branger B, Carbillon L, Chiesa C, Crenn-Hebert C, Dreyfus M, Dupont C, Fresson J, Huissoud C, Langer B, Morel O, Patrier S, Perrotin F, Raynal P, Rozenberg P, Rudigoz RC, Vendittelli F, Winer N, Deneux-Tharaux C, Kayem G; PACCRETA Study Group. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol. 2022 Jun;226(6):839.e1-839.e24. doi: 10.1016/j.ajog.2021.12.013. Epub 2021 Dec 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NI11061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.